赛诺医疗近3个交易日累计下跌19.1%

Core Viewpoint - Sino Medical experienced a significant decline in stock price, dropping 4.44% on August 22, with a total trading volume of 2.01 billion yuan and a turnover rate of 14.54% [1] Financial Performance - As of June 30, 2025, Sino Medical achieved total operating revenue of 240 million yuan, representing a year-on-year growth of 12.53% [1] - The company reported a net profit attributable to shareholders of 13.84 million yuan, marking a substantial year-on-year increase of 296.54% [1] - Key financial ratios include a current ratio of 2.395, a quick ratio of 1.917, and a debt-to-asset ratio of 29.39% [1] Stock Market Activity - Over the last three trading days, the stock has cumulatively declined by 19.1% [1] - On the same day, the net outflow of main funds was 208.97 million yuan, accounting for 10.4% of the trading volume, with large orders contributing to a net outflow of 187.02 million yuan, or 9.31% of the trading volume [1] Business Focus - Sino Medical specializes in the research, development, production, and sales of high-end interventional medical devices, with a product pipeline that includes key areas such as cardiovascular, cerebrovascular, and structural heart disease interventions [1] - The company's core product is the BuMA biodegradable drug-coated coronary stent system, which is designed and developed in-house and holds international intellectual property rights [1]